There is no specific evidence to suggest one class of antihypertensive agent over another in the management of BRAF inhibitor/MEK inhibitor–associated hypertension, but we suggest that ACE inhibitors or angiotensin receptor blockers should be used in patients with coexisting LVSD or proteinuria and in the absence of contraindications. The gene discussed is MAP2K7; the disease is Hypertension.